Zevra Therapeutics (ZVRA) Non-Current Deferred Tax Liability (2014 - 2020)

Zevra Therapeutics has reported Non-Current Deferred Tax Liability for 7 years, with the latest figure at $476000.0 in Q4 2020.

• For the quarter ending Q4 2020, Non-Current Deferred Tax Liability fell 11.85% year-over-year to $476000.0; the trailing twelve-month figure through Dec 2020 stood at $476000.0 (down 11.85% YoY), and the FY2020 full-year result was $476000.0, down 11.85% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2020 stood at $476000.0, down from $540000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $540000.0 in Q4 2019, with the low at $10000.0 in Q4 2018.
• Historically, Non-Current Deferred Tax Liability has averaged $275000.0 across 5 years, with a median of $260000.0 in 2017.
• Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability plunged 96.15% — and 2019, when it jumped 5300.0%.
• Zevra Therapeutics' Non-Current Deferred Tax Liability stood at $89000.0 in 2016, then jumped by 192.13% to $260000.0 in 2017, then sank by 96.15% to $10000.0 in 2018, then jumped by 5300.0% to $540000.0 in 2019, then dropped by 11.85% to $476000.0 in 2020.
• The last three Non-Current Deferred Tax Liability figures came in at $476000.0 (Q4 2020), $540000.0 (Q4 2019), and $10000.0 (Q4 2018), per Business Quant data.